Literature DB >> 12531251

Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma.

Achilleas D Theocharis1, Demitrios H Vynios, Nikoletta Papageorgakopoulou, Spyros S Skandalis, Dimitrios A Theocharis.   

Abstract

Glycosaminoglycans (GAGs) in proteoglycan (PG) forms or as free GAGs are implicated in the growth and progression of malignant tumors. These macromolecules were investigated in human gastric carcinoma (HGC) and compared with those in human normal gastric mucosa (HNG). We report that HGC contained about 2-fold increased amounts of GAGs in comparison to HNG. Specifically, HGC showed 3- and 2.5-fold net increase in chondroitin sulphate (CS) and hyaluronan (HA) contents, respectively. Dermatan sulphate (DS) was slightly increased, but the amount of heparan sulphate (HS) was decreased. Of particular, interest were the quite different sulphation profiles of CS and DS chains in HGC in which, non-sulphated and 6-sulphated disaccharide units were increased 10 and 4 times, respectively, in comparison to HNG. On PG level, three different populations were identified in both HNG and HGC, being HSPGs, versican (CS/DS chains) and decorin (CS/DS chains). In HGC, the amounts of versican and decorin were significantly increased about 3- and 8-fold, respectively. These PGs were also characterized by marked decrease in hydrodynamic size and GAG content per PG molecule. Analysis of Delta-disaccharide of versican and decorin from HGC showed an increase of 6-sulphated Delta-disaccharides (Delta di-6S) and non-sulphated Delta-disaccharides (Delta di-0S) with a parallel decrease of 4-sulphated Delta-disaccharides (Delta di-4S) as compared to HNG, which closely correlated with the increase of CS content. In addition, the accumulation of core proteins of versican and decorin in HGC was also associated with many post-translational modifications, referring to the number, size, degree and patterns of sulphation and epimerization of CS/DS chains. Studies on the modified metabolism of PGs/GAGs are under progress and will help in deeper understanding of the environment in which tumor cells proliferate and invade.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531251     DOI: 10.1016/s1357-2725(02)00264-9

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  38 in total

1.  Age-related differences in human skin proteoglycans.

Authors:  David A Carrino; Anthony Calabro; Aniq B Darr; Maria T Dours-Zimmermann; John D Sandy; Dieter R Zimmermann; J Michael Sorrell; Vincent C Hascall; Arnold I Caplan
Journal:  Glycobiology       Date:  2010-10-14       Impact factor: 4.313

Review 2.  Hyaluronan-CD44 interactions as potential targets for cancer therapy.

Authors:  Suniti Misra; Paraskevi Heldin; Vincent C Hascall; Nikos K Karamanos; Spyros S Skandalis; Roger R Markwald; Shibnath Ghatak
Journal:  FEBS J       Date:  2011-03-25       Impact factor: 5.542

3.  High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma.

Authors:  Matti Pukkila; Ari Kosunen; Kirsi Ropponen; Jukka Virtaniemi; Jari Kellokoski; Eero Kumpulainen; Risto Pirinen; Juhani Nuutinen; Risto Johansson; Veli-Matti Kosma
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

Review 4.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

Review 5.  Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.

Authors:  Achilleas D Theocharis; Chrisostomi Gialeli; Panagiotis Bouris; Efstathia Giannopoulou; Spyros S Skandalis; Alexios J Aletras; Renato V Iozzo; Nikos K Karamanos
Journal:  FEBS J       Date:  2014-11-06       Impact factor: 5.542

Review 6.  A role for proteoglycans in vascular disease.

Authors:  Thomas N Wight
Journal:  Matrix Biol       Date:  2018-02-27       Impact factor: 11.583

Review 7.  Intratumoral drug delivery with nanoparticulate carriers.

Authors:  Hillary Holback; Yoon Yeo
Journal:  Pharm Res       Date:  2011-01-07       Impact factor: 4.200

8.  Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding.

Authors:  Gerdy B ten Dam; Els M A van de Westerlo; Anurag Purushothaman; Radu V Stan; Johan Bulten; Fred C G J Sweep; Leon F Massuger; Kazuyuki Sugahara; Toin H van Kuppevelt
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

9.  Microanalysis of stomach cancer glycosaminoglycans.

Authors:  Amanda Weyers; Bo Yang; Jong-Hwan Park; Yong-Seok Kim; Sun-Moon Kim; Sang-Eok Lee; Fuming Zhang; Kyung Bok Lee; Robert J Linhardt
Journal:  Glycoconj J       Date:  2013-04-21       Impact factor: 2.916

10.  Versican expression in pharyngeal squamous cell carcinoma: an immunohistochemical study.

Authors:  M J Pukkila; A S T Kosunen; J A Virtaniemi; E J Kumpulainen; R T Johansson; J K Kellokoski; J Nuutinen; V-M Kosma
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.